Idogen AB logo

IDOGEN TR - Idogen AB Share Price

SEK0.001 0.0  0.0%

Last Trade - 12/03/20

Micro Cap
Market Cap £4.19m
Enterprise Value £1.09m
Revenue £n/a
Position in Universe th / 1783
Unlock IDOGEN TR Revenue
Relative Strength (%)
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 30 June 2020, Idogen AB revenues was not reported. Net loss decreased 21% to SEK14.2M. Lower net loss reflects Depreciation & Amortization decrease of 87% to SEK662K (expense), Other Operating Income increase from SEK2M to SEK4.2M (income), Personal Expenses decrease of 3% to SEK6M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -SEK0.37 to -SEK1.00.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


IDOGEN TR Revenue Unlock IDOGEN TR Revenue

Net Income

IDOGEN TR Net Income Unlock IDOGEN TR Revenue

Normalised EPS

IDOGEN TR Normalised EPS Unlock IDOGEN TR Revenue

PE Ratio Range

IDOGEN TR PE Ratio Range Unlock IDOGEN TR Revenue

Dividend Yield Range

IDOGEN TR Dividend Yield Range Unlock IDOGEN TR Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
IDOGEN TR EPS Forecasts Unlock IDOGEN TR Revenue
Profile Summary

Idogen AB is a Sweden-based company engaged in the healthcare industry. The Company is a research-driven entity developing a so called Tolerogenic Vaccine, a treatment concept for anti-drug antibodies, autoimmune diseases and transplant rejection. Its treatment is based on the patient's own dendritic cells (a type of white blood cell) and is taken out and reprogrammed in vitro and then given back to the patient. The Company is in pre-clinical phase and owns a platform technology, from which Idogen AB develops treatment for anti-drug antibodies, as well as autoimmune diseases that cannot be cured. In addition, the Company focuses on the transplantation market by reducing the need for immunosuppressive therapy after transplantation.

Last Annual December 31st, 2019
Last Interim June 30th, 2020
Public Since June 12, 2015
No. of Shareholders: n/a
No. of Employees: n/a
Sector Healthcare
Industry Biotechnology & Medical Research
Exchange AktieTorget Stock Exchange (Dual Listing)
Shares in Issue 9,371,654
Free Float (0.0%)
Eligible for
IDOGEN TR Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for IDOGEN TR
Upcoming Events for IDOGEN TR
Frequently Asked Questions for Idogen AB
What is the Idogen AB share price?

As of 12/03/20, shares in Idogen AB are trading at SEK0.001, giving the company a market capitalisation of £4.19m. This share price information is delayed by 15 minutes.

How has the Idogen AB share price performed this year?

Shares in Idogen AB are currently trading at SEK0.001 and the price has moved by % over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Idogen AB price has moved by % over the past year.

What are the analyst and broker recommendations for Idogen AB?

There are no analysts currently covering Idogen AB.

When will Idogen AB next release its financial results?

Idogen AB is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Idogen AB dividend yield?

Idogen AB does not currently pay a dividend.

Does Idogen AB pay a dividend?

Idogen AB does not currently pay a dividend.

When does Idogen AB next pay dividends?

Idogen AB does not currently pay a dividend.

How do I buy Idogen AB shares?

To buy shares in Idogen AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Idogen AB?

Shares in Idogen AB are currently trading at SEK0.001, giving the company a market capitalisation of £4.19m.

Where are Idogen AB shares listed? Where are Idogen AB shares listed?

Here are the trading details for Idogen AB:

Country of listing: Sweden
Exchange: AKT
Ticker Symbol: IDOGEN TR
What kind of share is Idogen AB?

We were not able to load our ranking data for Idogen AB

Is there a Idogen AB share price forecast 2020?

We were not able to load any forecast data for Idogen AB.

How can I tell whether the Idogen AB share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Idogen AB. Over the past six months, the relative strength of its shares against the market has been %. At the current price of SEK0.001, shares in Idogen AB are trading at % against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Idogen AB PE Ratio?

We were not able to find PE ratio data for Idogen AB.

Who are the key directors of Idogen AB?

We were unable to find the directors for Idogen AB.

Who are the major shareholders of Idogen AB?

Here are the top five shareholders of Idogen AB based on the size of their shareholding:

Similar to IDOGEN TR
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.